Blog Read the latest perspectives from our team of subject matter experts and others FDA Poised to Make Impact on Underrepresented Populations in Clinical StudiesDiversity Action Plans (DAPs) aim to improve data that the FDA receives by increasing the clinical enrollment of historically underrepresented participants. Increasing diversity in clinical trials not only makes the… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Diversity & Inclusion Drug Development Global Impact HCP Volunteers KOL Engagement Provider Data Research Post Industries:Commercialization Global Impact Payors Pharmaceutical & Biotechnology Provider Data Research KOL EngagementNurses: The Unsung Heroes in Pharma and Biotech for Health Equity and Medication AdherenceHealthcare providers are often the first line of defense in ensuring that people receive the medical treatment they need. But nurses are often overlooked as a solution to addressing health… Continue reading → Read the articleno Diversity & InclusionKOL EngagementFour Ideas for Pharma to Maximize the Influence of Digital Opinion Leaders in MedicinePharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education. With the rise… Continue reading → Read the articleno Diversity & InclusionDrug DevelopmentData Networks & Guiding Clinical Trials – Six Metrics for Powering Trials to Reach Vulnerable Patient PopulationsFor clinical operations and development clinical feasibility teams, diversity equity and inclusion and health equity leaders, as well as health economics and outcomes research (HEOR) teams, it is essential to… Continue reading → Read the articleno KOL EngagementThree Ways Field Medical Teams Can Close Care Gaps and Increase Scientific Share of VoiceAs the primary interface between healthcare providers (HCPs) and pharmaceutical companies, medical science liaisons (MSLs) have a unique opportunity to engage with HCPs in clinical discussions and bridge care gaps… Continue reading → Read the articleno Diversity & InclusionDrug Development3 Common Questions Related to Clinical Trial Performance DataOver the past decade, the cost and time impact to bring drugs to market have been increasing. With the recent trends in healthcare (more diversity and inclusion for both patients… Continue reading → Read the articleno CommercializationUnlocking Value-Based Care: How Pharma & MedTech Companies Can Thrive in a New Age of Private Payers and Population HealthAs the healthcare industry shifts to value-based care, private payers and population health are taking the lead in determining patient care. For pharma and med tech companies, this shift… Continue reading → Read the articleno«‹3456789›»